Arcellx

Arcellx Receivables

Delisted

The Accounts Receivable of Arcellx (ACLX) as of Oct 17, 2026 is 2.50 M USD.

Receivables

2.50 MUSD

Last updated:

Accounts Receivable of Arcellx is 2024 2.50 M USD. Accounts Receivable of Arcellx was 2023 - USD. It decreases by % lower compared to the previous year.

The Arcellx Receivables history

The Arcellx Receivables history
YEARReceivablesYoY
2.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx Inc, headquartered in Gaithersburg, US, is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer and other incurable diseases. The company, listed on February 4, 2022, operates with 209 employees and is advancing its lead program CART-ddBCMA in a pivotal Phase II trial for relapsed or refractory multiple myeloma. It also develops two clinical-stage ARC-SparX programs targeting BCMA and CD123 in various hematological malignancies. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Accounts Receivable of Arcellx is 2.50 M USD in 2024.

On Eulerpool you can find the complete historical development of Accounts Receivable Arcellx since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Arcellx

All Key Metrics — Arcellx